FY2024 EPS Estimates for Immunome Decreased by Analyst

Immunome, Inc. (NASDAQ:IMNM) – Research analysts at Leerink Partnrs decreased their FY2024 EPS estimates for shares of Immunome in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($2.23) for the year, down from their previous estimate of ($1.63). The consensus estimate for Immunome’s current full-year earnings is ($2.13) per share. Leerink Partnrs also issued estimates for Immunome’s Q4 2024 earnings at ($0.81) EPS, FY2025 earnings at ($4.17) EPS, FY2026 earnings at ($4.36) EPS and FY2027 earnings at ($3.97) EPS.

IMNM has been the topic of several other research reports. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Friday, October 25th. Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, Piper Sandler lowered their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has a consensus rating of “Buy” and a consensus price target of $28.83.

Immunome Stock Performance

Shares of IMNM opened at $9.44 on Monday. Immunome has a 52 week low of $6.93 and a 52 week high of $30.96. The stock has a 50 day moving average price of $13.02 and a two-hundred day moving average price of $13.75. The firm has a market capitalization of $588.93 million, a P/E ratio of -1.16 and a beta of 1.82.

Hedge Funds Weigh In On Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Swiss National Bank purchased a new stake in Immunome during the first quarter worth about $1,762,000. Sei Investments Co. purchased a new stake in shares of Immunome during the 1st quarter worth approximately $469,000. Vanguard Group Inc. increased its stake in shares of Immunome by 16.1% during the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock worth $49,847,000 after purchasing an additional 279,712 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Immunome by 602.1% in the 1st quarter. Acadian Asset Management LLC now owns 133,438 shares of the company’s stock worth $3,292,000 after purchasing an additional 114,433 shares during the period. Finally, EntryPoint Capital LLC lifted its stake in Immunome by 21,864.0% in the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after purchasing an additional 5,466 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Immunome news, CFO Max Rosett sold 14,380 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the transaction, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. This represents a 23.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is currently owned by corporate insiders.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.